Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04216251 · ClinicalTrials.gov registry record · Phase 1
PRevention Using EPA Against coloREctal Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT04216251: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT04216251 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04216251, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. \- The name of the study drug involved in this study is: \-- AMR101 (VASCEPA).
Interventions
- DRUG AMR101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04216251
The ClinicalTrials.gov registry entry for NCT04216251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMR101 is the first listed.
NCT04216251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04216251 about?
NCT04216251 is a clinical study titled "PRevention Using EPA Against coloREctal Cancer". This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. \- The name of the study drug involved in this study is: \-- AMR101 (VASCEPA).
What is the current status of trial NCT04216251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2020-12-09. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04216251?
The interventions under investigation include: AMR101 (DRUG).
Who is sponsoring clinical trial NCT04216251?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.